Monkeypox Cases: Update as of September 12, 2022

Update as of September 12, 2022, following reports of monkeypox cases in France and around the world. The next update will be released on September 15.

In early May 2022, cases of monkeypox with no direct link to travel to Central or West Africa—where the virus is present—or to people returning from such trips were reported in Europe and around the world. Since then, the disease has been subject to enhanced surveillance in both France and Europe.

Update on the Situation in France

As of 12:00 p.m. on September 12, 2022, 3,833 confirmed cases had been recorded in France, representing an increase of 112 cases since the update on September 6.

The distribution of confirmed cases by region of residence (or by region of reporting when the region of residence is unknown) is shown in Figure 1. The Île-de-France region has the highest number of cases (2,332, or 61%), followed by Occitanie (308 cases), Provence-Alpes-Côte d’Azur (264 cases), and Auvergne-Rhône-Alpes (246 cases); 20 cases are residents abroad.

For 1,097 confirmed cases (29%), the region of residence was unknown and was replaced by the region of reporting.
The vast majority of confirmed adult cases recorded to date are male, and 79 cases (2.1%) are female. The proportion of female cases has been increasing over the past few weeks. Among all confirmed cases reported in week 36 (unconsolidated data), 12.9% are women (compared to 5.7% in week 35 (according to consolidated data), 7.5% in week 34, and 5.8% in week 33). However, the number of confirmed cases reported in women remains low (a maximum of 12 cases reported in week 34 and week 36), against a backdrop of a decline in the total number of confirmed cases over the past several weeks. These data should therefore be interpreted with caution.

Nine (0.2%) children under the age of 15 were reported as confirmed cases. Confirmed adult cases have a median age of 36 years; 25% of adult cases are under 29 years old, and 25% are between 43 and 81 years old.

Among confirmed cases for which information is available, 81 (2.1%) were hospitalized due to their Monkeypox infection; this proportion has remained stable over time.

No deaths have been reported to date.

The distribution of cases by date of symptom onset (when known) is shown in Figure 2. The date of symptom onset for cases ranges from May 7 to September 5, 2022. Due to reporting delays, data from the past few weeks have not been consolidated. The reports received do not always mention the date of symptom onset. As an alternative to this information, the distribution of cases by date of reporting is presented in Figure 3.

These updated data suggest that the peak in infections occurred in late June/early July and that the number of confirmed cases has been trending downward since then. However, caution is warranted, as the summer period may have led to delays in diagnosis and reporting. Similarly, some individuals may not have sought medical care. Several other countries, particularly in Europe, have also observed a slowdown or even a decrease in the number of new cases reported in recent weeks.

Figure 1. Biologically confirmed cases of monkeypox (n=3,813 cases) by region of residence (or by region of reporting when the region of residence is unknown), France, May–September 2022 (data as of September 12, 2022 – 12:00 p.m.)

Figure 1. Cas confirmés biologiquement de variole du singe (n=3 813 cas) par région de résidence (ou par région de signalement lorsque la région de résidence est inconnue), France, mai-septembre 2022 (données au 12/09/2022 – 12h00)

Figure 2. Monkeypox cases (n=2,736 cases, number of missing data points: 1,097) by week of symptom onset, France, May–September 2022 (data as of September 12, 2022 – 12:00 p.m.).

Figure 2. Cas de variole du singe (n=2 736 cas, nombre de données manquantes : 1 097) par semaine de début des symptômes, France, mai-septembre 2022 (données au 12/09/2022 – 12h00).
The data for the past few weeks (in light blue) is not yet fully finalized.

Figure 3. Monkeypox cases (n = 3,833) by week of reporting, France, May–September 2022 (data as of September 12, 2022, at 12:00 p.m.). Data for the most recent week (in light blue) are not yet fully finalized.

Figure 3. Cas de variole du singe (n= 3 833 cas) par semaine de signalement, France, mai-septembre 2022 (données au 12/09/2022 – 12h00).
The data for the past week (in light blue) are not yet fully finalized. The dip in reported cases observed in week 28 (July 11–17) can be attributed to the July 14 holiday.

Preventive vaccination against monkeypox

For this week, deliveries of third-generation vaccines will be approximately 2,000 doses due to ample supplies at the various vaccination centers.

As a reminder, regarding the rollout of the vaccination campaign, as of September 8, 2022, 152,732 doses of the third-generation vaccine had been delivered by the Agency to the territories.

As of September 11, 2022, the total number of doses administered is 89,970 (source: Ministry of Health and Prevention).

Information and Prevention Initiatives

Given what has been observed in Europe regarding the disease, targeted communication was quickly implemented for men who have sex with men (MSM). The website sexosafe.fr, dedicated to the sexual health of MSM, is regularly updated with a summary of current knowledge on the subject and prevention measures. Poster, radio, and digital campaigns provide information to the public, complementing on-the-ground efforts. Since June 17, the digital campaign has generated nearly 898,991 clicks on banners and over 797,320 visits to the Sexosafe website.

All information on vaccination is updated weekly on the page for the general public and the page for healthcare professionals (accessible without a login) on the Vaccination-info-service website.

Prevention efforts are continuously adapted to the evolving situation and the current state of knowledge.

To facilitate access to information for vulnerable people in precarious situations, a visual tool—translated into 6 languages and developed with professionals working with these individuals—is available on Santé publique France

The MOBCO Newsletter No. 7, developed in collaboration with frontline workers, compiles a series of questions and answers on the topic of monkeypox. It is intended for professionals or volunteers in contact with people in precarious situations.

In France, ongoing surveillance of monkeypox through the mandatory reporting system has been strengthened, and information and alert messages are being sent to healthcare professionals. Discussions are also continuing with other European countries, the WHO, and the ECDC.

Monkeypox Info Service: A helpline to answer questions about monkeypox

The “Monkeypox Info Service” hotline is available daily from 8 a.m. to 11 p.m. at the toll-free number 0 801 90 80 69 (free calls and services; anonymous and confidential). This service is responsible for supporting prevention messages and protective measures, providing information on symptoms, treatments, and vaccination, and offering advice and referrals to care services.

Since the hotline opened in mid-July, 7,455 calls have been handled by the Monkeypox Info Service.

  • 257 calls were handled in week 36 (compared to 331 in week 35)

  • The number of daily calls has been steadily declining since Wednesday, August 10, 2022: an average of 45 calls handled per day (excluding weekends), whereas the average daily number of calls was 275 at the end of July and 225 at the beginning of August.

  • The topics discussed during the calls remain predominantly prevention measures (62% of calls). Questions on this topic frequently focus on vaccination and the various ways to access it.

  • Psychological and relational aspects account for 24% of the interviews (fear of being infected, risk of infecting others, fears related to potential complications of the disease, etc.).

Smallpox B (Mpox)

thematic dossier

Smallpox B (Mpox), formerly known as monkeypox, is a rare viral infectious disease caused by the monkeypox virus and transmitted primarily from rodents to humans, and then from person to person,...

Safe Sex

HIV and STI prevention, testing, and sexual orientation—the Sexosafe website addresses issues related to sexuality among men.